Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 19/20 | 0.96 |
| ▸ | RARB | P10826 | 8/20 | 0.96 |
| ▸ | RARG | P13631 | 8/20 | 0.96 |
| ▸ | RXRG | P48443 | 12/20 | 0.54 |
| ▸ | RXRB | P28702 | 10/20 | 0.54 |
| ▸ | RARA | P10276 | 4/20 | 0.50 |
| ▸ | PPARG | P37231 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4879243 | 1.00 | RXRA (0.96) | RXRARARBRARGRXRGRXRB | |
| SCHEMBL8359437 | 0.99 | RXRA (0.94) | RXRARARBRARGRXRGRXRB | |
| SCHEMBL8674942 | 0.99 | RXRA (0.94) | RXRARARBRARGRXRGRXRB | |
| SCHEMBL8359441 | 0.99 | RXRA (0.94) | RXRARARBRARGRXRGRXRB | |
| SCHEMBL8197218 | 0.98 | RXRA (1.00) | RXRARARBRARGRXRGRXRB | |
| SCHEMBL8197354 | 0.98 | RXRA (1.00) | RXRARARBRARGRXRGRXRB | |
| SCHEMBL8222641 | 0.90 | RXRA (0.78) | RXRARARBRARGRXRGRXRB | |
| SCHEMBL8196019 | 0.88 | RXRA (0.76) | RXRARARBRARGRXRGRXRB | |
| SCHEMBL8196021 | 0.88 | RXRA (0.76) | RXRARARBRARGRXRGRXRB | |
| SCHEMBL7840972 | 0.86 | RXRA (0.72) | RXRARARBRARGRXRGRXRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080255206-A1 | Rxr Agonists and Antagonists, Alone or in Combination with Ppar Ligands, in the Treatment of Metabolic and Cardiovascular Diseases | BOLLAG WERNER | 2008-10-16 | — | — | US | claimed |
| EP-0997455-A1 | Restricted 9-cis retenoids | American Cyanamid Company (US) | 2000-05-03 | — | — | EP | claimed |
| US-5968908-A | Restricted 9-cis retinoids | AMERICAN CYANAMID COMPANY (US) | 1999-10-19 | — | — | US | claimed |
| EP-0775103-B1 | RETINOIC ACID X-RECEPTOR LIGANDS | HOFFMANN LA ROCHE (CH) | 1999-06-09 | — | — | EP | claimed |
| US-5801253-A | Retinoic acid X-receptor ligands | HOFFMANN-LA ROCHE INC. (US) | 1998-09-01 | — | — | US | claimed |
| EP-0718285-A2 | Restricted 9-cis-retinoids | American Cyanamid Company (US) | 1996-06-26 | — | — | EP | claimed |
| US-20080255206-A1 | Rxr Agonists and Antagonists, Alone or in Combination with Ppar Ligands, in the Treatment of Metabolic and Cardiovascular Diseases | BOLLAG WERNER | 2008-10-16 | — | — | US | disclosed |
| US-20080255206-A1 | Rxr Agonists and Antagonists, Alone or in Combination with Ppar Ligands, in the Treatment of Metabolic and Cardiovascular Diseases | BOLLAG WERNER | 2008-10-16 | — | — | US | disclosed |
| EP-0718285-B1 | Restricted 9-cis-retinoids | AMERICAN CYANAMID CO (US) | 2001-04-11 | — | — | EP | disclosed |
| EP-0997455-A1 | Restricted 9-cis retenoids | American Cyanamid Company (US) | 2000-05-03 | — | — | EP | disclosed |
| US-5968908-A | Restricted 9-cis retinoids | AMERICAN CYANAMID COMPANY (US) | 1999-10-19 | — | — | US | disclosed |
| EP-0775103-B1 | RETINOIC ACID X-RECEPTOR LIGANDS | HOFFMANN LA ROCHE (CH) | 1999-06-09 | — | — | EP | disclosed |
| US-5801253-A | Retinoic acid X-receptor ligands | HOFFMANN-LA ROCHE INC. (US) | 1998-09-01 | — | — | US | disclosed |
| EP-0718285-A2 | Restricted 9-cis-retinoids | American Cyanamid Company (US) | 1996-06-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080255206-A1 | Rxr Agonists and Antagonists, Alone or in Combination with Ppar Ligands, in the Treatment of Metabolic and Cardiovascular Diseases | RXRA, RXRG, RXRB | RXRA 1/4885RARB 10/4885RARG 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.